Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

阿替唑单抗 贝伐单抗 医学 肿瘤科 内科学 免疫疗法 癌症 无容量 化疗
作者
Simon Johannes Gairing,Philipp C. Mildenberger,Jennifer Jane Gile,Fabian Artusa,Bernhard Scheiner,Catherine Leyh,Sabine Lieb,Friedrich Sinner,Vincent Joerg,Thorben W. Fruendt,Vera Himmelsbach,Nada Abedin,Cennet Sahin,Katrin Böttcher,Jasmin Schuhbaur,Simon Labuhn,James Korolewicz,Claudia Angela Maria Fulgenzi,Antonio D’Alessio,Valentina Zanuso
出处
期刊:JHEP reports [Elsevier BV]
卷期号:7 (3): 101295-101295 被引量:16
标识
DOI:10.1016/j.jhepr.2024.101295
摘要

Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly variable. This study aimed to (i) develop and validate a prognostic prediction model to estimate individual prognosis and (ii) compare it with established models. Methods: In this multicenter retrospective study, patients with HCC undergoing first-line immunotherapy with a + b from 24 centers (Europe, USA) were included. Statistical analysis and reporting followed the TRIPOD guidelines. The primary objective was overall survival (OS). A Cox model was developed and externally validated. Results: In total, 683 patients were included (training: 526, validation: 157). The C-reactive protein, albumin, bilirubin, lymphocytes, ECOG performance status, and extrahepatic spread (CABLE score) remained significantly associated with OS in Cox regression analysis. In the training set, the CABLE score had a higher discriminatory accuracy relative to ALBI, EZ-ALBI, mALBI, CRAFITY, PNI, NLR, PLR, and GPS (time-dependent AUC 0.79 and C-index 0.75 (95% CI 0.71-0.78) at 12 months). In the external validation set, the discriminatory performance of the CABLE score was comparable to ALBI, EZ-ALBI, and mALBI, but on average higher than PNI, CRAFITY, NLR, PLR, and GPS. In patients with Child-Pugh A, the CABLE score outperformed ALBI, EZ-ALBI, and mALBI in the first 9 months. We provide a web-based calculator for the CABLE score to allow estimation of individual prognosis for these patients (http://shiny.imbei.uni-mainz.de:3838/CABLE_Score/). Conclusions: The CABLE score shows good discriminatory performance in assessing the individual prognosis of patients undergoing first-line immunotherapy with a + b. Further validation studies are needed to investigate its performance compared with the ALBI score, in particular in subgroup analysis. Impact and implications: The CABLE score allows estimation of the prognosis of patients with unresectable hepatocellular carcinoma undergoing first-line immunotherapy with atezolizumab and bevacizumab at an individual level using our web-based calculator. This feature, as well as the evaluation of the score's added benefit through an extensive comparison with other established scores, can inform clinicians on their significance and may guide clinical decision-making in the context of a malignant disease where the prognosis has become highly variable. Further large validation studies are needed to investigate the incremental value of the CABLE score compared with the ALBI score, in particular in subgroups such as patients designated as Child-Pugh A.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鱼仔完成签到,获得积分10
刚刚
1秒前
没有脑袋完成签到,获得积分10
1秒前
纯真的德地完成签到 ,获得积分10
2秒前
lkc完成签到,获得积分10
2秒前
阿巴阿巴完成签到,获得积分10
4秒前
Nidhogg完成签到,获得积分10
4秒前
FashionBoy的应助被ZZ采纳,获得10
4秒前
陈子期完成签到,获得积分10
4秒前
Bobogee完成签到 ,获得积分10
5秒前
ENZO完成签到,获得积分10
6秒前
重要的板凳完成签到,获得积分10
6秒前
6秒前
qducly2026完成签到,获得积分10
6秒前
niuniu完成签到 ,获得积分10
7秒前
WXR完成签到,获得积分10
7秒前
pingping完成签到,获得积分10
7秒前
hetao286完成签到,获得积分10
7秒前
lili完成签到 ,获得积分0
7秒前
hqc8866发布了新的文献求助10
7秒前
不想做实验噜完成签到,获得积分10
7秒前
Aunt_Black完成签到,获得积分10
8秒前
111完成签到 ,获得积分10
8秒前
清爽老九完成签到,获得积分0
9秒前
hyjcnhyj完成签到,获得积分10
9秒前
酷酷柚子发布了新的文献求助10
9秒前
511完成签到 ,获得积分0
10秒前
Meteor636完成签到 ,获得积分10
10秒前
神勇千万完成签到,获得积分10
10秒前
典雅浩轩完成签到,获得积分10
10秒前
朱科源啊源完成签到 ,获得积分10
11秒前
123wzc完成签到 ,获得积分10
11秒前
LiGanZe完成签到,获得积分10
11秒前
12秒前
Defotls完成签到 ,获得积分10
13秒前
李爱国的应助被zzw采纳,获得10
13秒前
13秒前
纯真的棉花糖完成签到 ,获得积分10
13秒前
电池小白完成签到,获得积分10
14秒前
雨品完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173445
求助须知:如何正确求助?哪些是违规求助? 9565680
关于积分的说明 21781107
捐赠科研通 7767599
什么是DOI,文献DOI怎么找? 3431593
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476788